Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer. (April 2021) - Rugo, H.; O'Shaughnessy, J.; Song, C.; Broom, R.; Gumus, M.; Yamashita, T.; San Antonio, B.; Shahir, A.; Zimmermann, A.; Zagouri, F.; Reinisch, M.